OncoMatch/Clinical Trials/NCT05979818
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
Is NCT05979818 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Propranolol hydrochloride and Sintilimab for non small cell lung cancer.
Treatment: Propranolol hydrochloride · Sintilimab · Chemotherapy — This study is a prospective single-center Phase I clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety preliminarily in a small-size of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior exposure to any anti-PD-1 or anti-PD-L1, PD-L2, CD137, CTLA-4 antibody therapy, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: anti-PD-L1 therapy
Prior exposure to any anti-PD-1 or anti-PD-L1, PD-L2, CD137, CTLA-4 antibody therapy, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: anti-PD-L2 therapy
Prior exposure to any anti-PD-1 or anti-PD-L1, PD-L2, CD137, CTLA-4 antibody therapy, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: anti-CTLA-4 therapy
Prior exposure to any anti-PD-1 or anti-PD-L1, PD-L2, CD137, CTLA-4 antibody therapy, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: systemic cytotoxic chemotherapy
Exception: neoadjuvant/adjuvant chemotherapy or chemoradiotherapy completed ≥12 months prior to diagnosis of advanced/metastatic disease is permitted
Chemotherapy and chemoradiotherapy are permitted as neoadjuvant/adjuvant treatment as long as the treatment is completed at least 12 months prior to the diagnosis of advanced or metastatic disease
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 x 10^9/L; platelet count ≥ 100 x 10^9/L; hemoglobin ≥ 9.0 g/dL (no blood transfusion or erythropoietin-dependent administration within 7 days)
Kidney function
serum creatinine ≤1.5 × ULN or Cr clearance ≥60 mL/min; urine protein <2+ or 24-hour urine protein quantification <1g
Liver function
total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN in absence of hepatic metastases; ALT or AST ≤ 5 × ULN with hepatic metastases
Cardiac function
NYHA classification < 3; LVEF ≥ 50%; Baseline ECG showed no PR interval lengthened or atrioventricular block
Meet the following laboratory indicators... Heart function: the New York heart association (NYHA) classification < 3;Left ventricular ejection fraction（LVEF）≥ 50%; Baseline ECG showed no PR interval lengthened or atrioventricular block
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05979818 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages